BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30194661)

  • 1. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
    Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
    Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
    Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
    J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; ViganĂ² P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
    Barra F; Scala C; Ferrero S
    Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
    Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
    Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
    Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of elagolix in the treatment of endometriosis.
    Perricos A; Wenzl R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
    Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
    Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; A R S; Al Hendy A
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
    Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
    Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
    Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
    Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 20. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
    Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
    J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.